Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.52 |
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14344300 | 0.93 | FTO (0.55) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL9293647 | 0.86 | FTO (0.64) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL29368721 | 0.86 | FTO (0.64) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL27254940 | 0.85 | TTR (0.58) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL991216 | 0.84 | FTO (0.63) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL29353892 | 0.84 | FTO (0.63) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL2263499 | 0.84 | JAK2 (0.59) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL31435048 | 0.84 | TTR (0.59) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL20399862 | 0.84 | TTR (0.59) | JAK2NAALAD2FTONQO1MEN1 | |
| SCHEMBL15744221 | 0.83 | FTO (0.64) | JAK2NAALAD2FTONQO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999098-B2 | Triphosphate oligonucleotide modification reagents and uses thereof | SOLULINK BIOSCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-08-02 | — | — | US | disclosed |
| US-7173125-B2 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-02-06 | — | — | US | disclosed |
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2004-10-28 | — | — | US | disclosed |
| US-6686461-B1 | HYDRAZINO, OXYAMINO AND CARBONYL-BASED MONOMERS AND METHODS FOR LABELLING OF OLIGONUCLEOTIDES WITHOUT THE NEED FOR POST-SYNTHETIC MODIFICATION | SOLULINK BIOSCIENCE, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1305327-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | Schwartz, David A. (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | JAK2 4502/4885NAALAD2 1941/4885FTO 307/4885 |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | JAK2 4492/4885NAALAD2 1907/4885FTO 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.